Expression of membrane transporters and metabolic enzymes involved in estrone-3-sulphate disposition in human breast tumour tissues

Breast Cancer Research and Treatment

Volumn 145, Issue 3, 2014, Pages 647-661

  Banerjee, Nilasha ^a   Miller, Naomi ^b   Allen, Christine ^a   Bendayan, Reina ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Clinical tumour tissues; Estrone 3 sulphate; Hormone dependent breast cancers; Molecular target; Organic anion transporting polypeptides

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ESTRONE SULFATE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER B; ORGANIC ANION TRANSPORTER D; ORGANIC ANION TRANSPORTER E; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; SULFATASE; TESTOSTERONE 17BETA DEHYDROGENASE; 3 (OR 17)-BETA-HYDROXYSTEROID DEHYDROGENASE; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; CARRIER PROTEIN; ESTRONE; HYDROXYSTEROID DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; SLCO1A2 PROTEIN, HUMAN; SLCO2B1 PROTEIN, HUMAN; SLCO3A1 PROTEIN, HUMAN; SLCO4A1 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PATIENT; CANCER TISSUE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ESTROGEN METABOLISM; HISTOPATHOLOGY; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MCF 7 CELL LINE; MDA MB 231 CELL LINE; OPTICAL DENSITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; T47 D CELL LINE; ZR 75 CELL LINE; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BREAST TUMOR; FEMALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

17-HYDROXYSTEROID DEHYDROGENASES; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTRONE; FEMALE; HUMANS; MCF-7 CELLS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS;

EID: 84901631492     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2990-y     Document Type: Article

References (47)

1. National Cancer Institute Annual Report (2013) http://seer.cancer.gov/ statfacts/html/breast.html
2. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. doi: 10.1056/NEJMsr070105
3. Linden HM, Mankoff DA (2010) Breast cancer and hormonal stimulation: is glycolysis the first sign of response? J Nucl Med 51:1663-1664. doi: 10.2967/jnumed.110.078329
4. Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 76:27-36
5. Pasqualini JR, Chetrite GS (2005) Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 93:221-236. doi: 10.1016/j.jsbmb.2005.02.007
6. Geisler J (2003) Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 86:245-253
7. Van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH (1985) Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 45:2900-2906
8. Kendall A, Folkerd EJ, Dowsett M (2007) Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer. J Steroid Biochem Mol Biol 103:99-109
9. Santner SJ, Leszczynski D, Wright C, Manni A, Feil PD, Santen RJ (1986) Estrone sulfate: a potential source of estradiol in human breast cancer tissues. Breast Cancer Res Treat 7:35-44
10. Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR (2000) Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72:23-27
11. Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M, Maloche C (1996) Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81:1460-1464
12. Buxhofer-Ausch V, Secky L, Wlcek K, Svoboda M, Kounnis V, Briasoulis E, Tzakos AG, Jaeger W, Thalhammer T (2013) Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy. J Drug Deliv 2013:863539. doi: 10.1155/2013/863539
13. Banerjee N, Allen C, Bendayan R (2012) Differential role of organic anion-transporting polypeptides in estrone-3-sulphate uptake by breast epithelial cells and breast cancer cells. J Pharmacol Exp Ther 342:510-519. doi: 10.1124/jpet.112.192344
14. Hagenbuch B, Meier PJ (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653-665
15. Miki Y, Suzuki T, Kitada K, Yabuki N, Shibuya R, Moriya T, Ishida T, Ohuchi N, Blumberg B, Sasano H (2006) Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res 66:535-542
16. Meyer Zu, Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB (2008) Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res 68:9338-9347
17. Pizzagalli F, Varga Z, Huber RD, Folkers G, Meier PJ, St-Pierre MV (2003) Identification of steroid sulfate transport processes in the human mammary gland. J Clin Endocrinol Metab 88:3902-3912
18. Kindla J, Rau TT, Jung R, Fasching PA, Strick R, Stoehr R, Hartmann A, Fromm MF, Konig J (2011) Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue. Cancer Biol Ther 11:584-591
19. Pasqualini JR, Chetrite G, Nguyen BL, Maloche C, Delalonde L, Talbi M, Feinstein MC, Blacker C, Botella J, Paris J (1995) Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J Steroid Biochem Mol Biol 53:407-412
20. Conrad S, Kauffmann HM, Ito K, Leslie EM, Deeley RG, Schrenk D, Cole SP (2002) A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12:321-330
21. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y (2003) Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 64:610-618. doi: 10.1124/64.3.610
22. Fung AS, Jonkman J, Tannock IF (2012) Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel. Neoplasia 14:324-334
23. Huang W, Hennrick K, Drew S (2013) A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Hum Pathol 44:29-38. doi: 10.1016/j.humpath.2012.05.009
24. Klapczynski M, Gagne GD, Morgan SJ, Larson KJ, Leroy BE, Blomme EA, Cox BF, Shek EW (2012) Computer-assisted imaging algorithms facilitate histomorphometric quantification of kidney damage in rodent renal failure models. J Pathol Inform. doi: 10.4103/2153-3539.95456
25. Laurinavicius A, Laurinaviciene A, Ostapenko V, Dasevicius D, Jarmalaite S, Lazutka J (2012) Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol. doi: 10.1186/1746-1596-7-27
26. Konig J, Glaeser H, Keiser M, Mandery K, Klotz U, Fromm MF (2011) Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos 39:1097-1102. doi: 10.1124/dmd.110.034991
27. Tirona RG, Leake BF, Wolkoff AW, Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228. doi: 10.1124/102.043026
28. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB (2005) Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 33:676-682. doi: 10.1124/dmd.104.003244
29. Kis O, Zastre JA, Hoque MT, Walmsley SL, Bendayan R (2012) Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. Pharm Res. doi: 10.1007/s11095-012-0942
30. Ronaldson PT, Ashraf T, Bendayan R (2010) Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement of nuclear factor-kappaB and c-Jun N-terminal kinase signaling pathways. Mol Pharmacol 77:644-659
31. Purohit A, Chander SK, Woo LW, Parsons MF, Jhalli R, Potter BV, Reed MJ (2008) Inhibition of steroid sulphatase activity via the percutaneous route: a new option for breast cancer therapy. Anticancer Res 28:1517-1523
32. Nakata T, Takashima S, Shiotsu Y, Murakata C, Ishida H, Akinaga S, Li PK, Sasano H, Suzuki T, Saeki T (2003) Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. J Steroid Biochem Mol Biol 86:455-460
33. Suzuki T, Miki Y, Nakata T, Shiotsu Y, Akinaga S, Inoue K, Ishida T, Kimura M, Moriya T, Sasano H (2003) Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. J Steroid Biochem Mol Biol 86:449-454
34. Imai Y, Ishikawa E, Asada S, Sugimoto Y (2005) Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 65:596-604
35. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y (2002) Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res 93:231-235
36. Filipits M, Pohl G, Rudas M, Dietze O, Lax S, Grill R, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R (2005) Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. doi: 10.1200/JCO.2005.03.033
37. Rudas M, Filipits M, Taucher S, Stranzl T, Steger GG, Jakesz R, Pirker R, Pohl G (2003) Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat 81:149-157. doi: 10.1023/1025751631115
38. Banerjee N, Fonge H, Mikhail A, Reilly RM, Bendayan R, Allen C (2013) Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. PLoS One 8:e64069. doi: 10.1371/0064069
39. Maeda T, Irokawa M, Arakawa H, Kuraoka E, Nozawa T, Tateoka R, Itoh Y, Nakanishi T, Tamai I (2010) Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer. J Steroid Biochem Mol Biol 122:180-185. doi: 10.1016/j.jsbmb.2010.06.014
40. Nozawa T, Suzuki M, Takahashi K, Yabuuchi H, Maeda T, Tsuji A, Tamai I (2004) Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells. J Pharmacol Exp Ther 311:1032-1037. doi: 10.1124/104.071522
41. Nozawa T, Suzuki M, Yabuuchi H, Irokawa M, Tsuji A, Tamai I (2005) Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells. Pharm Res 22:1634-1641. doi: 10.1007/s11095-005-7096-0
42. Wlcek K, Svoboda M, Thalhammer T, Sellner F, Krupitza G, Jaeger W (2008) Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma. Cancer Biol Ther 7(1450-1455):6282
43. Suzuki M, Ishida H, Shiotsu Y, Nakata T, Akinaga S, Takashima S, Utsumi T, Saeki T, Harada N (2009) Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients. J Steroid Biochem Mol Biol 113:195-201. doi: 10.1016/j.jsbmb.2008.12.008
44. Howell A, Bundred NJ, Cuzick J, Allred DC, Clarke R (2008) Response and resistance to the endocrine prevention of breast cancer. Adv Exp Med Biol 617:201-211. doi: 10.1007/978-0-387-69080-3-19
45. Nicholson RI, Johnston SR (2005) Endocrine therapy - current benefits and limitations. Breast Cancer Res Treat 93(Suppl 1):S3-S10. doi: 10.1007/s10549-005-9036-4
46. Lumachi F, Luisetto G, Basso SM, Basso U, Brunello A, Camozzi V (2011) Endocrine therapy of breast cancer. Curr Med Chem 18:513-522
47. Lumachi F, Brunello A, Maruzzo M, Basso U, Basso SM (2013) Treatment of estrogen receptor-positive breast cancer. Curr Med Chem 20:596-604